Active Biotech Bilan de santé

Santé financière contrôle des critères 3/6

Active Biotech possède un total de capitaux propres de SEK1.4M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK14.9M et de SEK13.5M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 6.20m
Fonds propres	SEK 1.40m
Total du passif	SEK 13.50m
Total des actifs	SEK 14.90m

Mises à jour récentes de la santé financière

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03

Recent updates

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Feb 19

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Jul 27

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

May 07

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Jan 18

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ACTI ( SEK10.7M ) ne couvrent pas ses passifs à court terme ( SEK11.5M ).

Passif à long terme: Les actifs à court terme de ACTI ( SEK10.7M ) dépassent ses passifs à long terme ( SEK2.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: ACTI est sans dette.

Réduire la dette: ACTI n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ACTI dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ACTI dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 5.3 % chaque année

Active Biotech Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

Recent updates

New major risk - Shareholder dilution

Price target decreased by 67% to kr0.50

New major risk - Financial position

New major risk - Market cap size

New minor risk - Share price stability

Active Biotech AB (Publ) Reports Intention Inaugural Interocular Concentrations Achieves in A Clinical Bylistribution Study of Laquinimod Eye Drops

No longer forecast to breakeven

Active Biotech Provides Update on the Clinical Phase Ib/IIa Study with Tasquinimod in Relapsed Refractory Multiple Myeloma

Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Active Biotech AB (publ) Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Active Biotech AB (publ), Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Active Biotech AB (Publ) Provides Update on the Scheduled Clinical Program for 2024

Active Biotech AB (Publ) Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee

Forecast breakeven date pushed back to 2025

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Forecast to breakeven in 2024

Active Biotech AB (publ) Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

New major risk - Share price stability

Insufficient new directors

Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma

Active Biotech AB (Publ) Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops

Active Biotech AB (publ) to Report First Half, 2023 Results on Aug 24, 2023

Active Biotech's Announces Nomination Committee

Forecast to breakeven in 2024

Active Biotech AB (publ) to Report Fiscal Year 2022 Results on Feb 09, 2023

Active Biotech AB (Publ) Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage

Active Biotech AB (publ) announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Price target decreased to kr2.50

High number of new and inexperienced directors

Active Biotech AB (publ) to Report Q3, 2022 Results on Nov 03, 2022

Active Biotech Announces First Patient Dosed in the Combination Part of the Phase Ib/IIa Study of Tasquinimod in Multiple Myeloma

Active Biotech AB (publ) Announces First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Active Biotech AB (publ) Provides Status Update of its Clinical Naptumomab Project

Independent Director recently bought kr60k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Active Biotech Receive Milestone Payment from Neotx

New 90-day low: kr1.44

Active Biotech AB Appoints Elaine Sullivan as A Director

New 90-day low: kr1.50

New 90-day low: kr1.98

New 90-day low: kr2.15

New 90-day low - kr2.48

Earnings released

New 90-day high - kr2.88

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines